Loading clinical trials...
Loading clinical trials...
An Open-Label, Multicenter, Randomized, Controlled Study in Spontaneously Breathing Preterm Neonates With Respiratory Distress Syndrome to Compare Two Procedures for Porcine Surfactant (Poractant Alfa, CUROSURF®) Administration: A Less Invasive Method (LISA) During Non-invasive Ventilation (NIV) and the Conventional Administration During Brief Invasive Ventilation.
This study compared the administration of porcine surfactant (poractant alfa, Curosurf®) through a less invasive method (LISA), using a thin catheter, CHF 6440 (LISACATH®), during non-invasive ventilation (CPAP, NIPPV, BiPAP) with an approved conventional surfactant administration during invasive ventilation followed by rapid extubation in terms of short term and mid-term safety and efficacy in spontaneously breathing preterm neonates who have clinical signs of respiratory distress syndrome (RDS).
This study was an open-label, multicentre, randomized, controlled study of spontaneously breathing neonates with RDS. Neonates were evaluated according to the selection criteria and then randomized to surfactant treatment via LISA or standard administration procedure. The enrolment was staggered: the gestational age was restricted to 27+0 weeks up to 28+6 weeks for the first 15 neonates. Provided no safety concerns were raised, the enrolment was planned to be extended to the whole population (i.e. 25+0 weeks up to 28+6 weeks). Enrolled neonates were evaluated in a main phase of the trial until discharge or 40 weeks post-menstrual age (PMA), whichever came first. Their clinical status and neurodevelopment was to be assessed at 24-month corrected age as a separate stand-alone visit. The Sponsor decided to terminate the study early, due to uncertain sufficient availability of the CHF 6440 catheter.
Age
0 - 0 years
Sex
ALL
Healthy Volunteers
No
Chiesi Clinical Trial Site 84029
Little Rock, Arkansas, United States
Chiesi Clinical Trial Site 84001
Los Angeles, California, United States
Chiesi Clinical Trial Site 84002
Los Angeles, California, United States
Chiesi Clinical Trial Site 84013
Denver, Colorado, United States
Chiesi Clinical Trial Site 84026
New Britain, Connecticut, United States
Chiesi Clinical Trial Site 84003
Evanston, Illinois, United States
Chiesi Clinical Trial Site 84021
Peoria, Illinois, United States
Chiesi Clinical Trial Site 84023
Lexington, Kentucky, United States
Chiesi Clinical Trial Site 84028
Springfield, Massachusetts, United States
Chiesi Clinical Trial Site 84005
Worcester, Massachusetts, United States
Start Date
May 18, 2021
Primary Completion Date
August 13, 2022
Completion Date
August 13, 2022
Last Updated
November 7, 2023
33
ACTUAL participants
LISA combination product (Curosurf+catheter CHF6440)
COMBINATION_PRODUCT
Curosurf through conventional administration (endotracheal tube)
DRUG
Lead Sponsor
Chiesi Farmaceutici S.p.A.
NCT06774534
NCT06758492
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions